Plain-English translation of NCT06636175 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing a new imaging agent called that uses a small amount of radioactivity to help doctors detect blood cancers like multiple myeloma and lymphoma. Researchers want to confirm the medication works safely and reliably in both healthy volunteers and patients with blood cancers. The goal is to improve how well doctors can spot cancer in the body.
Current imaging methods don't always catch all areas where blood cancers are hiding or have returned after treatment. This medication may help doctors see cancer cells more clearly, which could lead to earlier detection and better treatment decisions.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll receive an injection of the radioactive imaging agent and then undergo PET/CT scans at several time points over one or two days. Depending on which group you're in, you may have quick scans starting right after the injection and a longer scan 2-4 hours later, plus another scan the next day. The entire process involves lying still in a scanner for up to 75 minutes at a time.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States